Uniphar Group PLC (UPR)
Euronext Dublin · Ireland · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 4.000 |
|---|---|
| 52-week range | 3.380 – 4.975 |
| Return, 1 month / 3 months | +1.4% / −10.5% |
| Return, 1 year / 3 years | +1.1% / +92.3% |
| Trend | Below its 200-day average |
| RSI (14) | 50 |
| Volatility (1 year) | 27.4% |
| Worst drawdown (1 year) | -22.0% |
| Average daily value traded | 1.38M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Uniphar Group is an Irish healthcare services company based in Dublin. It distributes medicines and healthcare products to pharmacies, hospitals and other healthcare providers, and it supplies supply chain and logistics support to manufacturers. The company also provides commercial services to healthcare brands, helping them bring products to market and reach clinicians and patients. Its customers include community pharmacies, hospital groups and healthcare product manufacturers, mainly across Ireland and the wider European region.
On this site Uniphar Group PLC appears as a stock on the Euronext Dublin (Ireland), code UPR, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 4 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Uniphar Group PLC (UPR) trades on the Euronext Dublin in Ireland. It last closed at EUR 4.000 on 27 October 2026.
Its price-based Market X-Ray is 35 out of 100 (a weak price profile), ranking 16 of 21 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 1.1% and over the last three months it fell 10.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Dublin
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 24 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -4.3% | ||
| From 52-week high | -18.7% | ||
| Momentum | 21 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -10.5% | ||
| 6-month return | -3.8% | ||
| 12-month return, skipping the last month | -0.3% | ||
| Stability (higher is calmer) | 50 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 27.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -22.0% | ||
| Liquidity | 52 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.38M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 2 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | +1.0% |
|---|---|
| 1 month | +1.4% |
| 3 months | −10.5% |
| 6 months | −3.8% |
| 1 year | +1.1% |
| 3 years | +92.3% |
| 5 years | −6.0% |
Signals
| 50-day / 200-day average | 4.054 / 4.180 |
|---|---|
| Golden / death cross (60 days) | Death, 15 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.113 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 20 Apr 2023 | EUR 0.0113 |
| 8 Sep 2022 | EUR 0.0061 |
| 21 Apr 2022 | EUR 0.0110 |
| 16 Sep 2021 | EUR 0.0056 |
| 22 Apr 2021 | EUR 0.0154 |
| 30 Apr 2020 | EUR 0.0073 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Dublin; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.